Liposarcoma clinical trials

The registry lists 160 studies for Liposarcoma across more than 10 countries. 36 are recruiting or about to start. 53 of them are mainly about Liposarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Liposarcoma, Myxoid too: 189 studies, 43 open.

Get an email when these change. Save the Liposarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 78
Recruiting: 29
Terminated: 14
Active, not recruiting: 13
Status unknown: 11
Withdrawn: 8

Phase

Phase 2: 91
Phase 1: 45
Phase 3: 24
Early Phase 1: 1

Where

United States: 101
France: 27
United Kingdom: 24
Canada: 21
Germany: 18
Belgium: 16

Who runs them

European Organisation for Research and Treatment of Cancer - EORTC (15) · National Cancer Institute (NCI) (14) · Memorial Sloan Kettering Cancer Center (9) · Baylor College of Medicine (4) · Dana-Farber Cancer Institute (4) · Children's Oncology Group (3) · Alliance for Clinical Trials in Oncology (3) · M.D. Anderson Cancer Center (3)

What is being tested here

Drugs under test in Liposarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Doxorubicin	2	6	15
Pembrolizumab	2	1	4
Abemaciclib	2	0	3
Liposomal doxorubicin	2	0	3
Ifosfamide	1	7	9
Trabectedin	1	1	9
Pazopanib	1	1	6
Selinexor	1	1	3
Retifanlimab	1	0	2
Palbociclib	1	0	2

Drug classes tested here Immune checkpoint inhibitors 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Alkylating agents 1 open · Antimitotic agents 5 · HDAC inhibitors 4

Coming up

5phase 3 studies under way

14studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Apr 2027Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma · Phase 3 · European Organisation for Research and Treatment of Cancer - EORTC
Sep 2027A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism · Phase 3 · Rezolute
Dec 2026Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) · Fox Chase Cancer Center
Dec 2026Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · National Cancer Institute (NCI)
Jan 2027BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma · Michael Wagner, MD
Jan 2027Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma · National Cancer Institute (NCI)
May 2027Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma · National Cancer Institute (NCI)
May 2027A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma · Memorial Sloan Kettering Cancer Center
Jun 2027Palbociclib and INCMGA00012 in People With Advanced Liposarcoma · Memorial Sloan Kettering Cancer Center
Jun 2027Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma · M.D. Anderson Cancer Center

Who these studies take

Of the 29 Liposarcoma studies recruiting now, 20 (69%) set no upper age limit and 8 (28%) stop at 75 or younger. 6 (21%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 29
Age	Women	Men
10	5 (17%)	5 (17%)
18	29 (100%)	29 (100%)
30	26 (90%)	26 (90%)
40	24 (83%)	24 (83%)
50	24 (83%)	24 (83%)
65	24 (83%)	24 (83%)
75	22 (76%)	22 (76%)
85	21 (72%)	21 (72%)

Across all 160 studies, recruiting or not: 19% stop at 75 or younger and 11% at 65; 28% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Liposarcoma studies take

Of 35 phase 2 interventional studies under Liposarcoma, half reached primary completion within 73 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	73 mo38–94 · 35 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Started recruiting1

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsOct 21, 2026NCT04557449

Studies

Recruiting first, then most recently updated. Showing 50 of 160. Browse all 160 → or search them.